


(Exhibit L to the Complaint), in which the Agency sought to apply its related drug policy to Librax. The Food and Drug Administration will not, in the future, base any adverse action concerning Librax on findings concerning the efficacy of the drugs listed in Paragraph 34 of the Complaint;


2. A new drug application for Librax was approved by the Food and Drug Administration on September 1, 1966. At that time, pursuant to the 1962 New Drug Amendments, the Food and Drug Administration determined that Librax was safe and effective for the indications set forth in its labeling;

3. The declarations set forth in Paragraphs 1 and 2 above are without prejudice to whatever rights the Food and Drug Administration may have to review its above-referenced approval of the new drug application for Librax. Similarly, plaintiff retains whatever rights it has to interpose procedural or substantive objections to any subsequent Agency action bearing on Librax.

Dated: July 17, 1973



Stuart J. Land
Arnold & Porter
1229 Nineteenth Street, N. W.
Washington, D. C. 20036

Dated: July 23, 1973


Ralph N. Del Deo
Crummy, O'Neill, Del Deo & Dolan
11 Commerce Street
Newark, New Jersey 07102

Attorneys for Plaintiff

Dated: July 26, 1973

HERBERT J. STERN
United States Attorney
Attorney for Defendants

By: BERNARD S. DAVIS
Assistant U.S. Attorney